A recent study reveals that patients who come off new GLP-1 drugs like Mounjaro or Wegovy may regain reduced body mass at a significantly accelerated pace than those who halt conventional lifestyle programs.
Research printed in a prominent medical journal shows that while obese people can lose a large proportion of their body weight while undergoing treatment, the weight returns at an estimated rate of nearly a kilo each month once they quit.
"Individuals buying these medications should be informed of the risk of quick rebound weight gain when the medication concludes," stated lead investigator Dr. Susan Jebb.
Such speed of recovery means a return to starting mass within about one and a half years.
Comparing Treatments
The study, which reviewed 37 of trials involving over 9,000 of patients, compared the results of these new drugs with conventional dieting.
Researchers note that people who lose weight through lifestyle changes alone generally have a more gradual weight regain—approximately 0.1 kg a month—post-intervention.
The Reason for the Quick Regain
Experts propose the mechanism of the drugs accounts for the amplified rebound.
These medications copy a body's own chemical called glucagon-like peptide-1, which helps regulate appetite.
"Artificially providing GLP-1 levels far above than normal might result in the system to produce less of its own natural GLP-1, and may also diminish responsiveness to its effects," said Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this medication means appetite is uncontrolled, making excessive eating far more likely."
A Chronic Issue?
The NHS suggest the jabs for people with obesity-related health risks, alongside recommended diet and exercise modifications.
Professionals say that, due to the significant potential of relapse, the treatment is often long-term.
This perspective is reinforced by pharmaceutical companies, who note that the results "highlight the long-term character of obesity," similar to managing conditions like diabetes.
Patient Testimonies
People who have stopped the jabs report a powerful resurgence of cravings.
"It felt as if a trigger flipping and you become ravenous," said one woman.
The struggle is worsened if individuals have not established permanent lifestyle or habit modifications during treatment.
Widespread Use
Figures indicate that a significant number of adults in the UK have tried weight-loss jabs in the past year, with desire being substantial.
- Use is higher among women than males.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
Ultimately, experts caution that while these medications are potent agents for shedding pounds, they are not a permanent cure and long-term success likely depends on integrated behavioural changes.
